Precigen Inc. (PGEN) has emerged as a notable biotechnology company following the full FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis in August 2025. With commercial momentum building, payer coverage expanding, and long-term durability data reinforcing the therapy's impact, attention now shifts to the company's upcoming catalysts.
These include the ongoing European regulatory review, further adoption metrics from the PAPZIMEOS Patient Hub, and clinical progress across its AdenoVerse immunotherapy pipeline. Together, these milestones have the potential to shape the company's trajectory in both the near and medium term.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.